CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

Valentina  Boni

Honoraria - IDEAYA Biosciences; Loxo

Consulting or Advisory Role - Guidepoint Global; OncoArt

Speakers' Bureau - Solti

Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst)

Travel, Accommodations, Expenses - START

Howard A.  Burris III

Employment - HCA Healthcare

Leadership - HCA Healthcare

Stock and Other Ownership Interests  - HCA Healthcare

Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst)

Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kyocera (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)

Expert Testimony - Novartis (Inst)

(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo (Inst); Pfizer (Inst)

Joyce F.  Liu

Consulting or Advisory Role - Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Mersana; Tesaro

Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Regeneron (Inst); Surface Oncology (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Merck

(OPTIONAL) Uncompensated Relationships - AstraZeneca; Merck

Alexander I.  Spira

Stock and Other Ownership Interests  - Lilly

Honoraria - Amgen; AstraZeneca/MedImmune; CytomX Therapeutics; Merck; Takeda

Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); incyte; Novartis

Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)

Hendrik-Tobias  Arkenau

Employment - Hospital Corporation of America

Honoraria - BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER

Mary J.  Fidler

Honoraria - AstraZeneca

Consulting or Advisory Role - Abbvie (I); AstraZeneca; Genentech; Genentech (I); Guardant Health; Guardant Health; Rakuten Medical (Inst)

Speakers' Bureau - Genentech; Merck

Research Funding - AstraZeneca (Inst); Biodesix; CytomX Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer/EMD Serono; Rakuten Medical (Inst)

Lee S.  Rosen

Research Funding - Bayer (Inst); CytomX Therapeutics (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Rgenix (Inst)

Randy F.  Sweis

Honoraria - Bristol-Myers Squibb; Exelixis; Medscape

Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Exelixis; Janssen Oncology; Mirati Therapeutics; Puma Biotechnology

Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst)

Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Exelixis

Nataliya Volodymyrivna  Uboha

Consulting or Advisory Role - AstraZeneca; EMD Serono; Flatiron Health; Gerson Lehrman Group; Incyte; ipsen; LEK; Lilly; Lilly; M3; Taiho Pharmaceutical

Research Funding - EMD Serono (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)

Rachel E.  Sanborn

Honoraria - Amgen; AstraZeneca

Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Celldex; Genentech/Roche; Peregrine Pharmaceuticals; Seagen; Takeda

Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck

Travel, Accommodations, Expenses - AstraZeneca; Five Prime Therapeutics; Janssen Oncology

Bert  O'Neil

Employment - Lilly

Consulting or Advisory Role - Bristol-Myers Squibb; Merck

James J.  Harding

Consulting or Advisory Role - Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Lilly

Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Polaris (Inst)

Patricia  LoRusso

Honoraria - Five Prime Therapeutics

Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME

Research Funding - Genentech (Inst)

Travel, Accommodations, Expenses - Genentech

Amy M.  Weise

No Relationships to Disclose

Javier  Garcia-Corbacho

No Relationships to Disclose

Iván  Victoria

No Relationships to Disclose

John W.  Frye

Employment - Aduro Biotech; CytomX Therapeutics

Stock and Other Ownership Interests  - CytomX Therapeutics

Travel, Accommodations, Expenses - Aduro Biotech; CytomX Therapeutics

Rachel  Li

Employment - CytomX Therapeutics

Stock and Other Ownership Interests  - CytomX Therapeutics

Honoraria - CytomX Therapeutics

Travel, Accommodations, Expenses - CytomX Therapeutics

Mark  Stroh

Employment - CytomX Therapeutics

Stock and Other Ownership Interests  - CytomX Therapeutics

Travel, Accommodations, Expenses - CytomX Therapeutics

Funda  Meric-Bernstam

Employment - MD Anderson Cancer Center

Honoraria - Dialectica; Sumitomo Group

Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; IBM; Immunomedics; Inflection Biosciences; Mersana; Origimed; PACT Pharma; Pieris Pharmaceuticals; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Xencor

Speakers' Bureau - Chugai Pharma

Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Seagen; Taiho Pharmaceutical